IKT

Business Context and Reporting Period

Company: Inhibikase Therapeutics, Inc. (IKT)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Inhibikase is a clinical-stage pharmaceutical company focused on developing therapeutics for cardiopulmonary diseases, specifically Pulmonary Arterial Hypertension (PAH). Its lead product candidate is IKT-001, a prodrug of imatinib mesylate designed to improve tolerability and efficacy compared to the original molecule. The company has no approved products and generates no revenue from product sales.

Key Financial Metrics

Material Changes vs. Prior Period

• Increased Operating Loss: Net loss increased by 75.4% to $48.26 million, driven primarily by higher R&D and SG&A expenses.
• R&D Expense Surge: R&D expenses rose 73.1% to $29.79 million. This includes a one-time non-cash charge of $7.4 million for acquired In-Process Research and Development (IPR&D) from the CorHepta acquisition and increased spending on the PAH program.
• SG&A Expense Surge: SG&A expenses increased 107% to $23.56 million, largely due to a $6.4 million increase in stock-based compensation and $4.2 million in personnel-related costs (including severance for former executives).
• Acquisition Activity: In February 2025, the company acquired CorHepta Pharmaceuticals, Inc. for approximately $15.0 million in stock consideration to expand its pipeline and scientific leadership.
• Capital Raises: The company raised approximately $107.6 million in net proceeds from an underwritten public offering in November 2025 and $99.6 million in net proceeds from a private placement in October 2024.
• Program Discontinuation: In January 2025, the company paused development of risvodetinib (IKT-148009) to focus resources on IKT-001, resulting in a decrease in Parkinson's disease program expenses.

Guidance, Outlook, and Risks

• Clinical Progress: The company has initiated the IMPROVE-PAH Phase 3 clinical study for IKT-001. This is a two-part adaptive study involving approximately 180 sites globally. Part A focuses on Pulmonary Vascular Resistance (PVR) at Week 24, and Part B focuses on 6-minute walk distance at Week 24.
• Regulatory Pathway: The FDA has confirmed the 505(b)(2) pathway is appropriate for IKT-001 approval. The company is in the process of applying for Orphan Drug Designation (ODD).
• Liquidity Outlook: Management believes existing cash, cash equivalents, and marketable securities ($178.8 million as of Dec 31, 2025) are sufficient to fund operations for at least the next twelve months.
• Key Risks:
  • Capital Requirements: The company expects to incur significant losses for the foreseeable future and will require additional financing to complete development and commercialization.
  • Clinical Trial Risks: Failure to demonstrate safety and efficacy in the Phase 3 trial, delays in enrollment, or adverse events could halt development.
  • Regulatory Uncertainty: Reliance on the 505(b)(2) pathway and potential changes in FDA policies or government funding (e.g., shutdowns) pose risks.
  • Competition: The PAH market is competitive, with new therapies like sotatercept (WINREVAIR) recently approved.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $178.8 million cash balance against the projected burn rate for the global Phase 3 trial, which has significant contracted costs (approx. $73.7 million total with CROs).
• Phase 3 Trial Design: Confirm the specifics of the adaptive Phase 3 design (Part A vs. Part B) and the criteria for transitioning between parts.
• CorHepta Integration: Assess the status of the CorHepta acquisition, specifically the vesting conditions for contingent consideration shares and the integration of their assets.
• Warrant Dilution: Review the terms of the Series A-1 and Series B-1 warrants issued in the October 2024 offering, including exercise prices ($1.37 and $1.49) and expiration triggers tied to clinical milestones.
• Patent Expiry: Verify the patent landscape for IKT-001, noting that some co-owned patents with Sphaera/Pivot may expire as early as 2033-2034, while others may extend to 2045.